Placebo Respimat

DRUG4 trials

Sponsors

Boehringer Ingelheim, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Conditions

AsthmaChronic Obstructive Pulmonary DiseaseCystic Fibrosis

Phase 2

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

CompletedNCT00737100

Boehringer IngelheimCystic Fibrosis

Start: 2008-09-30Updated: 2014-05-16

Phase 3

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

CompletedNCT01257230

Boehringer IngelheimAsthma

Start: 2010-12-31End: 2013-12-31Updated: 2014-09-05

Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma

CompletedNCT01340209

Boehringer IngelheimAsthma

Start: 2011-04-30End: 2013-04-30Updated: 2014-07-04

Phase 4

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

CompletedNCT02845752

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterChronic Obstructive Pulmonary Disease

Start: 2017-03-01End: 2018-08-06Updated: 2020-08-06

Related Papers

A randomized, crossover, placebo controlled, double-blind trial of the effects of tiotropium-olodaterol on neuromuscular performance during exercise in COPD.

2022-03-245 citations

A Randomized, Placebo Controlled, Double‐Blind, Crossover Trial of the Effect of Stiolto Respimat on Neuromuscular Performance During Cycling in COPD

The FASEB Journal2020-04-01

Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV<sub>1</sub>.

2019-07-1817 citations

Safety of tiotropium Respimat<sup>®</sup> in black or African-American patients with symptomatic asthma.

2019-07-022 citations

P45 Effect of tiotropium respimat® on seasonal asthma worsening in paediatric patients

2018-11-161 citations

P155 Safety of tiotropium respimat® add-on therapy in patients aged 6–17 years with symptomatic asthma

Thorax2016-11-151 citations

Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma

2016-09-011 citations

Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma

2016-09-01

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study

PLoS ONE2015-04-2088 citations

Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials.

2015-03-269 citations

Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results

PLoS ONE2014-09-0429 citations